Beyond GLP-1s: The next chapter of obesity care

by American Gastroenterological Association

edited by Sadie Harley, reviewed by Robert Egan

Sadie Harley

Scientific Editor

Meet our editorial team
Behind our editorial process

Robert Egan

Associate Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

proofread

The GIST Add as preferred source

The rapid rise of GLP-1 medications such as semaglutide and tirzepatide has transformed obesity treatment. Still, experts say medications alone are not enough to address one of the nation's most pressing chronic diseases.

A new commentary published in Gastroenterology, "Revisiting POWER in the GLP-1 Age," updates the landmark POWER (Practice Guide on Obesity and Weight Management, Education, and Resources) framework first published in 2017.

The paper reflects major advances in obesity care, including the emergence of highly effective anti-obesity medications, new evidence supporting endoscopic bariatric and metabolic therapies, expanded indications for bariatric surgery, and advances in precision medicine.

Key takeaways:

• GLP-1 receptor agonists have fundamentally changed the treatment landscape for obesity.
• The commentary incorporates the emerging concept of clinical obesity, which recognizes obesity as a chronic, systemic disease and highlights the limitations of relying on body mass index alone to assess health risks.
• Obesity care is increasingly moving toward a multidisciplinary model that combines medications, endoscopic therapies, and surgery.
• New evidence supports endoscopic sleeve gastroplasty and other endoscopic bariatric and metabolic therapies as effective treatment options.
• Advances in genetics and precision medicine may help physicians better match patients with obesity treatments that are most likely to be effective.
• Combining GLP-1 medications with endoscopic or surgical interventions may produce greater and more durable weight loss than either approach alone.

The paper emphasizes the important role gastroenterologists and hepatologists play in obesity management. These specialists routinely care for patients with obesity-related conditions such as metabolic dysfunction-associated steatotic liver disease (MASLD), gastroesophageal reflux disease (GERD), gallbladder disease, and gastrointestinal complications associated with obesity.

Publication details

Revisiting POWER in the GLP-1 Age, Gastroenterology (2026). DOI: 10.1053/j.gastro.2026.04.016

Journal information: Gastroenterology

Key medical concepts

ObesityGlucagon-Like Peptide-1 Receptor AgonistsWeight Loss Surgery

Clinical categories

GastroenterologyWeight managementClinical pharmacology Provided by American Gastroenterological Association Who's behind this story?

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: Beyond GLP-1s: The next chapter of obesity care (2026, June 17) retrieved 17 June 2026 from https://medicalxpress.com/news/2026-06-glp-1s-chapter-obesity.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.